Ligand Pharmaceuticals PE ratio LGND

Share price divided by earnings per share over the last twelve months, since 2012.

Today, Oct 23, 2026: 32.3×
10-year median: 37.7×
Against its 10-year history: 41st; percentile: 0 is its lowest day, 100 its highest
10-year range: 2.0× to 215×
Peer median: 60.3×

Ligand Pharmaceuticals' PE ratio is 32.3× as of Oct 23, 2026: a share price of $303.53 against $9.40 of earnings per share over the last twelve months.

That is below its ten-year median of 37.7×, close to the middle of its last ten years.

Over that time it ranged from 2.0× in May 2019 to 215× in Mar 2018.

The median for 10 large drugmakers of a similar size is 60.3×.

PE ratio over time

median 37.7×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	32.3×	28.7×	99.8×
2025	94.6×	42.3×	98.2×
2024	43.5×	14.9×	92.1×
2023	86.0×	34.4×	86.2×
2022	44.6×	15.8×	44.6×
2021	24.2×	22.5×	37.8×
2020	2.2×	2.0×	2.3×
2019	2.4×	2.0×	14.4×
2018	11.6×	11.3×	215×
2017	86.3×	82.3×	197×
2016	186×	4.5×	196×
2015	5.7×	5.1×	132×
2014	60.1×	52.8×	113×
2013	66.2×	64.1×	89.6×
2012	80.2×	65.0×	172×

Against its peers

Companies in Drug Manufacturers - General nearest Ligand Pharmaceuticals' size, closest first, today.

Company	PE ratio
LGNDLigand Pharmaceuticals	32.3×
KNSAKiniksa Pharmaceuticals International	79.1×
AMRXAmneal Pharmaceuticals	41.6×
ALKSAlkermes plc.	115×
TGTXTG Therapeutics	19.8×
PTGXProtagonist Therapeutics	134×
INDVIndivior Pharmaceuticals	12.4×
CORTCorcept Therapeutics	204×
ARQTArcutis Biotherapeutics	142×
LQDALiquidia	30.7×
OGNOrganon	17.9×
Peer median	60.3×

Where Ligand Pharmaceuticals ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Ligand Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.